• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Week in review for April 20-24, 2020: Investors tracking companies developing therapies for cancer, neurological diseases

April 27, 2020
By Peter Winter
A quick look back at top stories.
Read More

Money raised by biopharma: 2020 vs. 2019

April 24, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-April 23, 2020

April 24, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Biopharmaceutical collaborations: March 2020

April 24, 2020
Biopharma licensings, joint ventures and collaborations, including: Alector, Allogene, Alnylam, Amgen, Astellas, Astrazeneca, Bayer, Biocon, Biofrontera, Biogen, Biontech, Brightinsight, Bristol-Myers Squib, Canndoc, Celator, Codexis, Cytomx, Cytori, Debiopharm, Eli Lilly, Emergent Biosolutions, Epivax, Evotec, Forge, Forma, Fujifilm, Fujitsu, Generex, Hoth, Hypera, Ideaya, I-Mab, Immix, Isoprene, Jiangsu Alphamab, Lonza, Mannkind, Medigene, Medivir, Merck, Merrimack, Mochida, Neurorx, Nicox, Novartis, Novavax, Novotech, Oasmia, Ono, Peptidream, Pfizer, Regeneron, Revive, Sanofi, Sciclone, Shionogi, Simcere, Sorrento, Sutro, Takeda, Trianni, Ultragenyx, Vaxart, Vir, Xencor, Xoma, Zai Lab.
Read More
Illustration of big fish eating three smaller fish

Completed biopharmaceutical mergers & acquisitions: March 2020

April 24, 2020
Completed biopharma M&As, including: Asahi Kasei, Axim, Danaher, Domain, Foamix, GE Healthcare, Menlo, Neurofit, Prestwick Chemical, Psilocin, Recode, Revive, Sapphire, Transcriptx, Veloxis.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: March 2020

April 24, 2020
Deals between biopharma companies and government or nonprofit entities, including: Acelrx, Allovir, Altimmune, Anabios, Arcturus, Astellas, Avectas, Berkeley Lights, Celldex, Cyclica, Daiichi Sankyo, Diverse, Dyadic, Grifols, Ideaya, IMV, Isoplexis, Janssen, Kuur, Lift, Lonza, Pluristem, Ridgeback, Shanghai Junshi, Sihuan, SK Chemicals, Themis, Wuxi Biologics, Zelluna, Ziphius.
Read More

Biggest gainers and losers for the week of April 20-24, 2020

April 24, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More

Med-tech gainers and losers for April 20-24, 2020

April 24, 2020
The top 10 med-tech stock gainers and losers for the week.
Read More
Brain and DNA

Investors still tracking companies developing therapies for cancer, neurological diseases

April 22, 2020
By Peter Winter
Although the product pipeline for vaccines and therapeutics targeting COVID-19 is top of mind right now, investors are also keeping a close eye on companies involved in the development of medicines targeting cancer and the central nervous system. According to financings tracked by BioWorld and deals and grants logged in Cortellis, the therapeutic areas of cancer, neurology and psychiatric attracted the highest amounts of investments last year with a collective $101.9 billion and $27.5 billion raised, respectively.
Read More
Stock chart, upward arrow

Investors show confidence in biopharmas developing COVID-19 therapies

April 20, 2020
By Peter Winter
Although the COVID-19 pandemic has decimated the economy and played havoc with the financial markets, there are promising signs that investors are slowly returning as infection curves begin to flatten thanks to social distancing measures. There is no doubt that they are showing confidence in those leading biopharmaceutical companies who they believe hold the keys to unlocking cures for the deadly infection. In addition, amid the intense activity related to COVID-19 research and development, the FDA did take some time to approve several new medicines, reinforcing the fact that innovation has not been completely throttled by the industry’s focus on the pandemic.
Read More
Previous 1 2 … 226 227 228 229 230 231 232 233 234 … 264 265 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • Stock chart, upward arrow

    An early stage 85% remissions rate in AML drives Aptevo’s stock surge

    BioWorld
    An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • 3D illustration of a chain of amino acid or biomolecules called protein

    Alphadesign: AI creating proteins from scratch

    BioWorld Science
    The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe